Vitamin D: The Pendulum

No supplement's reputation has swung harder than vitamin D's: a wonder-nutrient candidate in the 2000s, a disappointment after the big trials, and — with a calmer read of the evidence — a reliable gap-filler for the people who are actually low. This page walks the pendulum and extracts what survives each swing.

Three Eras of the Vitamin D Story

The pendulum is best understood as three consecutive readings of the same data. The 2000s saw observational studies link low 25-hydroxyvitamin D to nearly every disease researchers measured — heart disease, cancer, diabetes, depression, mortality — which fueled the era of universal supplementation. The 2010s brought the skeptical turn: randomized trials started reporting null results, and analyses like the Autier review (Lancet Diabetes & Endocrinology, 2014) argued that low vitamin D was mostly a marker of ill health rather than a cause of it. The trial era that followed settled the question for the replete: VITAL (2019), ViDA (2017), and D-Health (2022) all found no cardiovascular, diabetes, or mortality benefit. Where the field has landed is the deficiency-first position — the pendulum's resting point.

What VITAL Actually Found

VITAL (New England Journal of Medicine, 2019) is the trial that anchored the modern view: 25,871 US adults — men 50 and older, women 55 and older — took 2,000 IU of vitamin D3 daily or placebo for a median of 5.3 years. The primary endpoints, invasive cancer and major cardiovascular events, showed no significant difference. The finding people remember is a secondary one: fewer cancer deaths in the vitamin D group (hazard ratio 0.83 in the original report), which strengthened and became statistically significant with extended follow-up. That is a real observation, but it is one secondary endpoint in one trial — the honest read is "interesting, not settled."

The Same Null, Three Continents

VITAL was not an outlier. ViDA (New Zealand, JAMA Cardiology, 2017) randomized 5,110 adults to monthly high-dose vitamin D or placebo and found no cardiovascular benefit. D-Health (Australia, Lancet Diabetes & Endocrinology, 2022) gave 21,315 adults aged 60 to 84 a monthly 60,000 IU for five years: all-cause mortality was essentially unchanged (hazard ratio 1.04) and there was no cardiovascular effect. DO-HEALTH (Europe, JAMA, 2020) tested 2,000 IU daily plus omega-3 and an exercise program in 2,157 adults over 70 — none of the three interventions produced significant benefits on the pre-specified primary outcomes. Three continents, tens of thousands of participants, one consistent message: in adults who start with adequate levels, more vitamin D does not measurably move the big outcomes.

What D3 Plausibly Does

• 🦴 Bone, with calcium — vitamin D drives calcium absorption; deficiency correction supports bone density and, combined with calcium, reduces fracture risk in deficient older adults. The bone evidence is the oldest and steadiest part of the file, and it is owned by the Bone Health topic.
• 🚶 Falls in deficient older adults — an early meta-analysis (BMJ, 2009) found supplementation reduced falls in older adults, an effect later large trials tempered. The consensus now: correcting deficiency helps balance-related outcomes; supplementing replete adults does not add much.
• 💪 Muscle function — severe deficiency causes muscle weakness, and correcting it improves strength. The evidence for meaningful gains above sufficiency is thin.
• 🛡️ Immune modulation — vitamin D supports innate immune responses, and some trials suggest modest reductions in acute respiratory infections in deficient populations. The size of that effect in replete adults remains debated.

Why the Observational Data Misled

The gap between the 2000s enthusiasm and the trial era nulls has a mechanism worth understanding, because the same pattern misleads in every supplement category. Low vitamin D travels with poor health for reasons that have little to do with the vitamin: sick people go outside less, obesity sequesters vitamin D in fat tissue and lowers measured levels at identical sun exposure, and aging thins the skin's capacity to synthesize it. When you correct for those factors — or better, randomize — much of the association evaporates (Autier et al., 2014). Low vitamin D is often a symptom of the conditions it was once blamed for causing. The pendulum swung because the field confused a marker with a mechanism.

Who Still Benefits

None of the nulls erase the deficiency story. When 25-hydroxyvitamin D is genuinely low, correcting it matters — and specific groups are far more likely to be low.

The common maintenance band when a deficiency is confirmed is 800–2,000 IU daily, with a recheck in three to four months to confirm the dose is moving the level without overshooting. The Institute of Medicine sets the tolerable upper intake at 4,000 IU daily for adults — routine dosing above that is clinician territory.

Questions, Answered Briefly

• ☀️ Should I take vitamin D "just in case"? A modest daily dose is reasonable insurance for an indoor northern winter without testing; if you want certainty, test — the testing page covers how.
• ⚖️ Is 30 ng/mL the right target? The Endocrine Society says sufficiency starts at 30; the Institute of Medicine considers 20 adequate. The gap is unresolved, which is why treating to a number matters less than correcting clear deficiency.
• 🩸 How fast does my level move? Individual responses vary widely, which is exactly why a recheck after three to four months beats assuming the dose.
• 📉 What about the cancer-mortality signal? Real, secondary, from one trial, and worth following — but it does not overturn the primary nulls, and it is not a reason for everyone to supplement.

Related Topics